|
|
Home  CMSC Online For CMSC Members Annual Meetings
|
Annual Meeting 2008 Highlights Symposia |
|
|
2008 CMSC Annual Meeting
Multiple Sclerosis: Comprehensive Approaches to Complex Challenges
May 28-31, 2008
Symposia
Please note that the following presentations have been converted to Adobe PDF. Copying of any image is disabled and only low-resolution printing is allowed.
Back to the 2008 Annual Meeting Highlights main page
- Primary Progressive Multiple Sclerosis
Kathleen Hawker, MD; Paul O’Connor, MD
The symposium will address the most current data on PPMS including research findings.
Level: Advanced - MS Genetics in Latin America
Victor Rivera, MD
MS and related diseases have become prevalent neurological disorders in Latin America with the consequent necessity to understand the factors that genetics and ancestry may play in their presence in the region and who are the susceptible individuals. This symposium is presented by LACTRIMS addressing the actual understanding of genetics among individuals with MS and other very visible demyelinating diseases in the area, including NMO.
Level: Basic, Intermediate and Advanced - Neuromyelitis Optica
Brian Weinshenker, MD
The symposium will cover what neuromyelitis optica is, how it differs from standard MS, recent advances in identifying the target antigen (Aquaporin – 4), and optimal patient management.
Level: Advanced - Diagnostic Criteria and Clinical Spectrum
Dean Wingerchuk, MD - Pediatric Neuromyelitis Optica
Sean Pittock, MD - Asian Optic Spinal MS: Same Disease or Different?
Jun-ichi Kira, MD - Pathobiology of Neuromyelitis Optica
Brian Weinshenker, MD, FRCP(C) - Natural History and Treatment
Bruce Cree, MD, PhD, MCR - Vignettes
Brian Weinshenker, MD, FRCP(C)
- Hidden Disabilities in Multiple Sclerosis
George H. Kraft, MD, MS
It is well known that MS affects many CNS domains. Testing for various deficits is widely done and used in developing treatment programs. But is this adequate? Dr. Kraft will present the problem: Do care providers really understand MS patient’s needs? Or are we missing something? This symposium will present new information on understanding patients’ perspectives to help clinicians provide better care for their MS patients. Dr. Yorkston will discuss the results of focus groups conducted on issues related to communication with health providers about the hidden aspects of MS and Dr. Amtmann will present how state-of-the-art psychometric methods are being used to create robust tools to assess patient reported outcomes in both clinical practice and clinical trials research. Finally, Dr. Ehde will discuss management of some of the important “hidden” symptoms of MS: pain, depression, and cognitive problems.
Level: Intermediate - CIS - What Do We Know? What Do We Do?
Mark Freedman, MD
CIS has become an important time point for making an early diagnosis of MS, ensuring a comprehensive work-up for ruling out other entities and introducing the possibility of effective treatment. The faculty will review the “top 10” reasons for addressing this early time point, the most common entities confused with MS, the important features to consider on an early MRI and finally discuss the treatment options. We will conclude with a few illustrative and provocative cases that beckon audience input and discussion.
Level: Intermediate and Advanced - Advances in MRI in MS
Nancy Richert, MD, PhD, Chair
New areas of MRI research discussing structural and functional alterations in MS as well as repair strategies will be discussed.
Level: Advanced - Outcome Measures for Gait and Fatigue: A CMSC Consensus Conference Summary
Brian Hutchinson, PT, MSCS
The symposium will focus on presenting the results of a CMSC consensus conference on outcome measures for gait and fatigue.
Level: Intermediate - Introduction to Consensus Conference Process
Brian Hutchinson, PT, MSCS - Outcome Measures for Gait
Susan Bennett, PT, EdD, NCS, MSCS - Fatigue in MS: Gaining Consensus for the Clinical Setting
Susan Forwell, PhD, OT(C), FCAOT - Summary of Outcome Measures and Next Steps
Brian Hutchinson, PT, MSCS
- Report on the Lesion Project
Claudia Lucchinetti, MD
The Multiple Sclerosis Lesion Project (MSLP) is an international collaborative study funded by the United States Multiple Sclerosis Society (RG-3185-A-2; RG-3185-B-3; 3/2000-4/2008) to examine the clinical, radiologic, serologic and genetic correlates of the MS lesion. Over its tenure, this study has accumulated an enormous resource of interactive investigators, invaluable research experience, and a carefully organized tissue/clinical/radiographic/genetic database. The MSLP is path-breaking due to the availability of brain tissue from patients with both early and late MS, its international scope, the comprehensive clinical and neuroimaging follow-up, an integrated, multidisciplinary approach, and a comprehensive international database. This unique resource provides an opportunity to explore mechanisms of MS lesion formation, as well as identify and evaluate clinical and paraclinical markers for diagnosis and stratification of MS patients.
The current symposium will provide the latest update on the past accomplishments, and ongoing studies of the MS Lesion Project. Dr. Lucchinetti, who is Principal Investigator of the MSLP, will begin by discussing the current evidence for pathological heterogeneity in MS as it relates to both lesional activity and disease duration. Dr. Bradley Erickson will next review the results of both retrospective and prospective neuroimaging studies that support the concept of pathogenic heterogeneity in early MS. Next, Dr, Mark Keegan will discuss current evidence suggesting that specific MS pathological subtypes may be associated with a beneficial response to plasma exchange. Dr. Francisco Quintana will then describe recent data indicating specific serological immune signatures may be associated with specific pathological subtypes in MS. Dr. Gabriele De Luca will then present recent data regarding the potential relationship of disease modifying genes with defined MS pathological outcomes. Lastly, Dr. Shanu Roemer will describe the evidence for cortical pathology in early MS, and discuss potential clinical and pathogenic implications of this early cortical involvement.
The MSLP has impacted our approach to MS research by emphasizing the importance of characterizing patterns of demyelination and tissue injury in MS, thereby facilitating the identification of key molecular and immunological pathways of tissue injury which may have important clinical and therapeutic implications.
Level: Advanced - Pathological Heterogeneity: Clinical and Pathogenic Implications
Claudia Lucchinetti, MD - MRI Correlations of Pathological Subtypes
Bradley Erickson, MD, PhD - Plasma Exchange and Immunopathology
Mark Keegan, MD, FRCP(c) - Unique Immune Signatures Associated with MS Pathological Subtypes
Francisco Quintana, PhD - Genetic-Pathological Associations in MS
Gabriele Carmine DeLuca, MD, PhD - Cortical Pathology in Early MS
Shanu Roemer, MD
- Disorders of Mood and Affect in Patients with MS
Anthony Feinstein, PhD, MD
Dr. Anthony Feinstein will begin the symposium by giving a broad overview of the disorders of mood and affect. Dr. Ralph Benedict will present data looking at correlations between brain imaging abnormalities and alterations in personality. Dr. David Mohr will present on the question of how stress may affect mood in patients with MS. Finally, Dr. Peter Arnett will provide data on the longitudinal course of symptomatology in MS patients.
Level: Intermediate and Advanced - Advanced MS
Jodie Haselkorn, MD, MPH
This multi-disciplinary national panel of experts will address issues common to working with individuals with advanced MS that are frequently not discussed or written about.
Level: Basic, Intermediate and Advanced - Defining and Treating MS Relapses
James P. Simsarian, MD
This symposium will examine relapses in Multiple Sclerosis. How do we define relapses clinically, immunologically and by MRI measurements, what do relapses mean for the patient, what treatments are available, how do we treat relapses and what are the implications of relapses for the patient.
Level: Basic and Intermediate - What is Comprehensive Care in MS?
Susan Bennett, PT, EdD, NCS, MSCS
This will be a multi-center presentation with three centers speaking about the types of services they provide that meet the comprehensive needs of our patients. Examples of what is included in comprehensive care would be: Medical social worker or health psychologist, group counseling, 1:1 counseling; Patient education programs focused on “Living well with Multiple Sclerosis”; Wellness visits with a nurse practitioner or member of comprehensive team; Nutritional counseling; Support Groups; Rehabilitation team; Neuropsychologist.
Level: Basic - Introduction
Susan Bennett, PT, EdD, NCS, MSCS - The Schapiro Center Approach to Comprehensive Care – 30+ Years of Evolution
Randall Schapiro, MD - Comprehensive Care in an Ever Evolving Healthcare System
Patricia Kennedy, RN, CNP, MSCN - Case Presentations from the Comprehensive Care Center of the Jacobs Neurological Institute
Margaret Umhauer, RN, NP, MSCN and Mary Karpinski, LMSW
|
|
